pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,560 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1389Fierce Biotech708BioSpace698BioPharma Dive524raps234onclive165fda recalls113
therapy area
allOncology12306Rare Disease3217Immunology2862Cardiology2745Hematology2177Pulmonology2138Vaccines
  • Mid-size pharma firms drive surge in biopharma M&A activity
    The article notes that 2026 is shaping up as one of the busiest years for biopharma mergers and acquisitions on record. Unlike previous years dominated by large multinational companies, a broader…
    Endpoints · 6mo agoDealNeutral↗ source
  • Prevention and personalized skin care highlighted as future direction for melanoma oncodermatology
    Dr. Beth McLellan, a dermatologist, emphasizes that preventing radiation-induced skin damage is becoming a central focus in melanoma care. She also points out the need for equitable access to scal…
    onclive · 6mo agoPositive↗ source
← prev
page 120 of 143
next →
fda medwatch111
globenewswire health73
fda press59
1796
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • U.S. officials urge Germany to raise drug prices in trade talks
    U.S. Trade Representative Jamieson Greer and senior health adviser Chris Klomp met with German Ambassador Jens Hanefeld at a breakfast briefing to press Germany to increase the price it pays for pr…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • DOJ alleges Yale and UCLA med schools discriminate against white and Asian applicants
    The U.S. Justice Department sent a letter to Yale School of Medicine on Thursday accusing it of illegal discrimination against applicants who are not Black or Hispanic. The allegation follows a si…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Biopharma M&A stays robust as companies shift focus from megadeals to smaller targets
    The article notes that despite a slowdown in large megadeals, overall merger and acquisition activity in the biopharma sector remains strong. Companies are adopting multi‑pronged strategies to add…
    Endpoints · 5mo agoDealNeutral↗ source
  • PSA Blood Test Found to Lower Prostate Cancer Deaths, Review Shows
    A new Cochrane review concludes that prostate-specific antigen (PSA) screening is likely to reduce deaths caused by prostate cancer. The analysis combined data from six trials involving roughly 80…
    STAT · 6mo agoPositive↗ source
  • Takeda to Pay $13.6 Million to Resolve DOJ Claims of Doctor Kickbacks for Antidepressant Trintellix
    Takeda Pharmaceuticals has agreed to pay $13.6 million to settle federal allegations that it provided illegal kickbacks to physicians to encourage prescriptions of its antidepressant, Trintellix. T…
    STAT · 5mo agoRegulatoryNegative↗ source
  • Amgen tightens 340B program rules, expanding pharmacy claims data requirements
    Amgen announced it is expanding the data it requires from pharmacies that dispense its products under the federal 340B drug discount program. The new policy will obligate participating pharmacies…
    Endpoints · 5mo agoRegulatoryNeutral↗ source
  • Aardvark to unblind rare disease trial after FDA places full clinical hold; Alumis issues verdict on Acelyrin asset
    Aardvark's rare disease candidate is under a full clinical hold by the FDA, which has paused all dosing and data collection. The company says it intends to unblind the trial data despite the hold,…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • OncLive poll highlights top GI cancer abstracts and interest areas for ASCO 2026
    OncLive conducted a poll among its audience to gauge which gastrointestinal cancer abstracts are expected to generate the most interest at the upcoming ASCO Annual Meeting. The poll results identi…
    onclive · 6mo agoNeutral↗ source
  • Older adults warn that changing pill colors and shapes cause dangerous confusion
    Barbara Wolf, a 73‑year‑old from Birmingham, Alabama, takes six medications each day and relies on the color, shape and size of each pill to keep her regimen straight. She recently received a refi…
    STAT · 6mo agoNegative↗ source
  • Supreme Court Keeps Mail Delivery of Abortion Pill Mifepristone in Place
    The Supreme Court issued a ruling on Thursday that preserves the ability to ship the abortion medication mifepristone through the postal service. The decision leaves in place the existing safety r…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • Dr Croll reviews study linking tumor size changes on scans to pathological outcomes after neoadjuvant therapy in kidney cancer
    Dr Benjamin Croll, MD, presented findings from a recent investigation into the relationship between radiographic size changes and pathological response in renal cell carcinoma patients receiving ne…
    onclive · 5mo agoNeutral↗ source
  • Dr Garzotto reviews efficacy of aglatimagene besadenovec with valacyclovir and radiation in localized prostate cancer
    Dr Mark Garzotto presented data on a novel therapeutic approach for localized prostate cancer that combines the gene therapy agent aglatimagene besadenovec with the antiviral drug valacyclovir and…
    onclive · 5mo agoNeutral↗ source
  • US pushes Germany on drug pricing while FDA faces turmoil and biotech trials advance, says Pharmalittle roundup
    The newsletter notes that U.S. lawmakers are intensifying pressure on Germany to lower the prices of pharmaceuticals, a move that could reshape cross-border pricing negotiations. At the same time,…
    STAT · 6mo agoNeutral↗ source
  • AC Immune CEO Andrea Pfeifer Retires After 23 Years, Company Begins CEO Search
    AC Immune announced that its chief executive Andrea Pfeifer will step down after a 23‑year tenure. Pfeifer, who has guided the biotech through multiple development programs, said she will retire a…
    Endpoints · 6mo agoNeutral↗ source
  • Nonprofits launch Zillow-style marketplace to match abandoned gene and cell therapies with new developers
    Two nonprofit groups announced the launch of an online marketplace designed to give abandoned cell and gene therapy projects a chance for redevelopment. The platform, unveiled at the American Socie…
    Endpoints · 6mo agoPositive↗ source
  • Alcohol’s deadly toll is overlooked as a public-health crisis, STAT explores why
    STAT’s weekly video series highlighted that alcohol kills more Americans than any other drug, yet it is rarely framed as a public‑health emergency. The contrast between its mortality impact and pub…
    STAT · 6mo agoNeutral↗ source
  • GU experts poll top abstract topics for ASCO 2026 meeting
    A poll of genitourinary oncology specialists was conducted to gauge interest in upcoming ASCO 2026 abstracts. Participants used OncLive’s social media platform to nominate the abstracts they expec…
    onclive · 6mo agoNeutral↗ source
  • Roswell Park Researchers Join 2026 World Indigenous Cancer Conference
    Roswell Park Comprehensive Cancer Center staff took part in the 2026 World Indigenous Cancer Conference, a global gathering focused on cancer issues affecting Indigenous peoples. The conference br…
    onclive · 5mo agoPositive↗ source
  • Basking Biosciences appoints former Pulmocide chief medical officer Lance Berman
    Basking Biosciences announced the addition of Lance Berman as its new chief medical officer. The appointment was highlighted in a recent industry column that tracks personnel changes. Berman comes…
    STAT · 5mo agoNeutral↗ source
  • OncLive launches weekly quiz on recent FDA oncology approvals
    OncLive released a weekly news quiz dated May 15, 2026, inviting readers to test their knowledge of recent oncology developments. The quiz focuses on three new FDA approvals in the oncology space…
    onclive · 5mo agoNeutral↗ source
  • Remembering Craig Venter: The Complex Legacy Behind the Human Genome Race
    Former NIH archivist Zachary Utz reflects on the recent death of Craig Venter, a prominent figure in genomics known for challenging conventional scientific approaches. Venter’s private company Cel…
    STAT · 6mo agoNeutral↗ source
  • Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancer
    A recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
    onclive · 6mo agoPositive readoutPositive↗ source
  • AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancer
    AstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…
    Endpoints · 6mo agoPositive readoutPositive↗ source